This review (2020) explored recent advances in natural psychoplastogens (psychedelics) as antidepressant agents. The study noted that these compounds are effective in rapid structural and functional rearrangement of neural systems by targeting mechanisms that were previously implicated in the development of depression. The study observed the evidence that they expend potent acute and long-term positive effects, beyond the treatment of psychiatric disorders with many of them being naturally occurring compounds, like psilocybin and DMT.
Increasing prevalence and burden of major depressive disorder presents an unavoidable problem for psychiatry. Existing antidepressants exert their effect only after several weeks of continuous treatment. In addition, their serious side effects and ineffectiveness in one-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens. These compounds are capable of fast structural and functional rearrangement of neural networks by targeting mechanisms previously implicated in the development of depression. Furthermore, evidence shows that they exert a potent acute and long-term positive effects, reaching beyond the treatment of psychiatric diseases. Several of them are naturally occurring compounds, such as psilocybin, N,N-dimethyltryptamine, and 7,8-dihydroxyflavone. Their pharmacology and effects in animal and human studies were discussed in this article.
Depression is described as a common, disabling and rising global health problem for which existing antidepressants are imperfect: they typically require several weeks to produce benefit, have substantial side effects, and fail to help roughly one-third of patients. The extracted text frames multiple biological contributors to major depressive disorder (MDD), including monoamine dysregulation, hypothalamic-pituitary-adrenal (HPA) axis hyperactivation, chronic low-grade inflammation and impaired neuroplasticity, and summarises how traditional antidepressants (TCAs, MAOIs, SSRIs) address some but not all of these mechanisms. Against this background, the paper introduces the concept of psychoplastogens — chemically diverse compounds that rapidly induce structural and functional neural plasticity and converge on downstream pathways such as TrkB and mTOR. Benko and colleagues set out to review naturally occurring psychoplastogens (notably serotonergic psychedelics such as psilocybin and DMT, and the flavone 7,8-dihydroxyflavone) with respect to their mechanisms, animal and human evidence, and potential therapeutic relevance for depression and related conditions.
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Olson, J. A. · Neuroscience Insights (2018)
Nichols, D. E. · Pharmacological Reviews (2016)
Nutt, D. J. · Dialogues in Clinical Neuroscience (2019)
The authors first define psychoplastogens as agents that rapidly promote neural plasticity and then describe two traditional mechanistic frameworks for depression: the monoamine hypothesis (historical observations linking monoamine depletion to depression and the action of monoaminergic antidepressants) and the neurotrophic hypothesis (reduced BDNF/TrkB signalling, impaired long‑term potentiation, dendritic atrophy in PFC and hippocampus, and stress‑related changes). These sections provide the biological rationale for targeting plasticity pathways. Mechanistically, the review emphasises that serotonergic psychedelics exert broad receptor activity with 5-HT2A receptor activation playing a central role. Activation of 5-HT2A (a Gq/11-coupled receptor) increases intracellular calcium, activates PLCβ and PKC, and stimulates MAPK; psychedelics also induce a distinct receptor conformation that engages phospholipase A2 (PLA2) in addition to PLCβ, a form of "biased agonism". Psilocin, for instance, was reported to activate PLA2 with 30-fold greater potency relative to PLCβ when compared with serotonin. The authors note that psychedelics ultimately engage pathways including mTOR and TrkB and that these downstream effects are linked to increased neurite length, dendritic spine number and overall network complexity. Animal studies summarised by Benko show that 5-HT2A receptors are highly expressed on layer V pyramidal neurons in prefrontal cortex (PFC) and that their activation raises excitatory post-synaptic potentials. Psychedelics (and synthetic 5-HT2A agonists such as DOI) produced anxiolytic-like effects in some rodent tests and facilitated cue‑based fear extinction, whereas results varied across models and strains. Notably, some substances produce anxiogenic effects in the immediate post-acute period, but positive behavioural changes persist for hours to days after the drugs are eliminated, implying durable functional remodelling. Knock-out models lacking 5-HT2A show increased anxious and depressive‑like behaviour, supporting a role for this receptor in mood regulation. Human evidence emphasises the perceptual and psychological effects of psychedelics that are mediated by 5-HT2A receptors and blocked by ketanserin or atypical antipsychotics. Clinical trials and experimental studies have produced promising results for psilocybin in treatment‑resistant depression and existential distress in terminal illness: reductions in depressive and trait anxiety measures have been reported from 1 week up to at least 6 months post-treatment in some studies, with improvements in well-being and life satisfaction. Psilocybin has been designated a ‘‘breakthrough therapy’’ for MDD by the U.S. FDA and progressed to Phase III, while LSD trials are in Phase II. Ayahuasca (DMT plus MAOI) produced rapid reductions in anxiety and depression symptoms with benefits reported up to 3 weeks in clinical studies. Neuroimaging findings indicate acute disruption of the default mode network (DMN) during psychedelic experience with evidence of post‑acute DMN strengthening; the authors highlight the hypothesis that DMN disruption may enable remodelling of networks underlying negative rumination. Some sustained clinical improvements were correlated with mystical‑type experiences during dosing sessions. The review then turns to 7,8-dihydroxyflavone (7,8-DHF), a small‑molecule TrkB agonist. 7,8-DHF binds the TrkB extracellular domain and produces prolonged TrkB phosphorylation in vivo, unlike the transient effect of BDNF. Bioavailability limitations due to rapid hepatic conjugation are noted; a prodrug, R13, increased oral bioavailability from 4.6% to ~10.5% and improved plasma and brain exposure, with beneficial effects in animal models of amyloid pathology and cognition. In vitro studies, however, failed to reproduce TrkB phosphorylation, and the authors report proposed explanations including in vivo metabolism to an active species or methodological artefacts. Animal data for 7,8-DHF include TrkB‑dependent antidepressant‑like effects in forced swim and tail suspension tests, rescue of synaptic plasticity and cognitive deficits in aged or disease models, neuroprotective effects across several neuronal populations, and improvements in models of neurodegeneration and stroke. The extracted text states that no human clinical trials of 7,8‑DHF for MDD have been reported. Safety considerations summarised in the review indicate that physiological effects of psychedelics are usually moderate (transient increases in heart rate and blood pressure, headaches, gastrointestinal symptoms). Psychological adverse effects — transient anxiety, confusion, and perceptual disturbances — can occur but trials under controlled conditions report low rates of serious adverse events; the authors cite approximately 2000 administered doses of psilocybin without serious adverse events in the studies referenced. Population data reportedly show no association between lifetime psychedelic use and increased mental illness or suicidal behaviour and even a lower need for recent mental health treatment in psychedelic users. Nonetheless, strict exclusion criteria are advised for individuals with personal or family histories of schizophrenia, mania or bipolar disorder because of a potential risk of precipitating psychosis in susceptible people. The authors also discuss theoretical concerns for 7,8-DHF: BDNF–TrkB signalling is implicated in neuropathic pain and could conceivably strengthen pathological nociceptive pathways, a potential contraindication.
Benko and Vranková interpret the collected evidence as supportive of psychoplastogens being a promising new class of rapid‑acting antidepressant agents. They position psychedelics and TrkB agonists within the broader shift away from slow‑onset monoaminergic treatments toward interventions that directly modulate neuroplasticity through mTOR and BDNF–TrkB signalling. The authors note that ketamine’s clinical adoption provides precedent for fast‑acting, plasticity‑focused treatments and that clinical findings for psilocybin, ayahuasca and related agents extend this paradigm. The authors acknowledge several uncertainties and limitations. Clinical data for serotonergic psychedelics are still emerging, with many positive findings coming from small or open‑label studies; the review does not report a systematic search strategy or quantitative synthesis in the extracted text. For 7,8‑DHF, translational gaps are highlighted: in vivo TrkB activation and behavioural benefits are promising, but in vitro failures to replicate TrkB phosphorylation, poor oral bioavailability, and the need for improved prodrugs underscore the need for further pharmacokinetic and mechanistic work. Safety limitations include the potential for transient psychological distress during sessions, and the authors caution about use in individuals at risk for psychosis or bipolar disorder. They further raise a specific biological concern for 7,8‑DHF because BDNF–TrkB signalling can exacerbate neuropathic pain in some contexts. Implications the authors emphasise are the need for more rigorous clinical trials (including larger, controlled studies and longer follow-up), improved medicinal chemistry for TrkB agonists (as exemplified by the R13 prodrug), and careful patient selection and psychotherapeutic integration when using serotonergic psychedelics. The review also notes ongoing medicinal chemistry efforts to develop DMT isosteres with psychoplastogenic but reduced hallucinogenic properties, while recognising that the subjective, mind‑altering experience may itself contribute to therapeutic outcomes.
The authors conclude that natural psychoplastogens — particularly serotonergic psychedelics and TrkB‑targeting flavones — offer a compelling, mechanistically distinct approach to treating depression because of their ability to rapidly induce neural plasticity and produce durable psychological benefits after a small number of sessions. They caution that while initial safety data are reassuring under controlled conditions, further research is required to confirm efficacy, refine dosing and delivery (for example via prodrugs such as R13), and delineate contraindications. Ultimately, Benko and colleagues call for additional preclinical and clinical studies to determine whether these agents can be integrated into psychiatric practice as alternatives or complements to conventional long‑term antidepressant treatments.
Depression is the most common and debilitating mental disease. Its prevalence and burden have been steadily rising in the past decades. For example, in 1990, the World Health Organization (WHO) projected that depression would increase from 4th to 2nd most frequent cause of world-wide disability by 2020. In 2008, it was ranked as the 3rd and projected to be the 1st leading cause of disability by 2030. Neurotransmitter and neuroplasticity dysregulation, the hypothalamic-pituitary-adrenal axis (HPA-axis) hyperactivation, and chronic subclinical inflammation have been identified as contributing factors along with psychological ones. Selective reuptake inhibitors, targeting monoamines, have been developed to normalize most of these changes. Although these drugs have been enjoying some success and are able to induce remission, approximately one-third of patients show no response to any class, while other patients respond only partially. Because of this, new therapeutic approaches are being intensively developed. In recent years, research using deep-brain, vagus nerve and transcranial magnetic stimulation, and dissociative anesthetics or psychedelics have produced promising results. Major depressive disorder (MDD) patients suffer from symptoms of depressed mood, anhedonia, sadness, lack of energy, insomnia, hypoactivity, anorexia, decreased libido, concentration, and fatigue to a varying degree throughout an episode. In atypical depression, hyperphagia and hypersomnia are present rather than their opposite. Additionally, patients often ruminate excessively and manifest decreased self-confidence, guilt, and helplessness. The disorder is often accompanied by excessive anxiety or psychotic symptoms. In the most difficult cases, patients are severely disabled, unable to perform any usual activities, and neglect self-care. Most of these symptoms have been found to have some neural correlates. If MDD is left undiagnosed, patients are at a greater risk of suicide, serious comorbid conditions, such as cardiovascular or neurodegenerative disease, loss of employment, or severed relationships.
Psychoplastogens are substances capable of rapid induction of structural and functional neural plasticity with the ultimate modulation of cognitive faculties. This recently defined classincludes a growing number of chemically diverse compounds working through common molecular mechanisms. The concept is based upon similar effects of serotonergic psychedelics, several flavonoids, and ketamine, of which the latter has been recently approved for the treatment of resistant forms of depression. Though they target different receptors, in the end, they promote activation of tropomyosin kinase B (TrkB) and mammalian target of rapamycin (mTOR).
Monoamine hypothesis started with an accidental observation that reserpine, a drug used to treat high blood pressure, also causes behavioral depression in rodents and humans. This finding has been adopted as an experimental model of depression. On a molecular level, reserpine blocks the transport of monoamines into vesicles and causes their profound depletion in the long term. This is manifested by typical symptoms of depression-anhedonia, anergia, and low mood. The subsequent development of drugs targeting the metabolism of monoamines has resulted in the advent of tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), and other compounds with the combined mechanism of action. In general, these compounds lead to an increase in synaptic monoamine concentration and are able to induce complete or partial remission of the symptoms. However, the first signs of alleviation come often after several weeks of continuous treatment. Thus, there has been a need for a greater understanding of their mechanism of action. Subsequently, HPA-axis dysregulation and neurogenic theory of depression have been elaborated. These help to explain the delay between the beginning of treatment and the onset of action by SSRIs. It has been shown that chronic SSRI treatment repairs these abnormalities. Nevertheless, the monoamine hypothesis has withstood the testing and provides a partial explanation of the disease. Substantial evidence has been amassed during the last 50 years of research. For example, depressed patients have lower 5-hydroxyindoleacetic acid to 5-HT ratio (5-HIAA/5-HT) in cerebrospinal fluid, a sign of decreased serotonergic neurotransmission. Chronic antidepressant treatment normalizes these changes, along with symptom reduction. Moreover, acute and chronic tryptophan depletion lowers 5-HT reserves, which changes reactivity to affective stimuli and leads to higher aggression or anxiety in humans. Post mortem studies on suicidal patients show marked changes in the 5-HT system in the prefrontal cortex, hippocampus, or amygdala. Similar results come from animal research-chronic unpredictable stress or other models of depression reduce 5-HT concentration in the prefrontal cortex and limbic system. SSRIs are able to compensate for these changes. Furthermore, variations in genes involved in monoamine metabolism have been linked to depression. Serotonin signaling is also indispensable in neurogenesis maintenance, which is another principal mechanism involved in the development of depression(see below).
Impaired neurogenesis and neuroplasticity are also considered to be an important mechanism involved in the pathogenesis of depression. In order to adapt behaviorally to external stimuli (including stressful ones), animals need to modify the functional connectivity of their brain networks. In the adult mammalian brain, these changes are driven by two opposite synaptic processes-long term potentiation and long-term depression, LTP and LTD, respectively. LTP is further conceptualized into two partially overlapping phases-early (e-LTP) and late (l-LTP). The former involves modification (e.g., phosphorylation, nitrosylation) of existing synaptic proteins, while the latter is characterized by expression of new synaptic proteins at both pre-and post-synaptic membranes. The extracellular signal initiating the expression of synaptic proteins has been identified to be a brain-derived neurotrophic factor (BDNF). Its secretion is stimulated by the sole activity of neurons (both pre-and post-synaptic) expressed as calcium concentration ([Ca 2+ ]). Increased [Ca 2+ ] leads to activation of the cascade, including protein kinase C (PKC), mitogen-activated protein kinase (MAPK), and cAMP response-element binding protein (CREB). CREB directly up-regulates the expression of the bdnf gene. After its release into the synaptic cleft, BDNF binds to TrkB receptor at both preand post-synaptic membrane. Its stimulation leads to the activation of MAPK, mTOR, and CREB (forming a positive feedback loop). Activation of these pathways promotes cell survival and proliferation. Besides synaptic protein synthesis, neurons treated with BDNF undergo axonal and dendritic spine sprouting and synaptogenesis. All of these changes ultimately contribute to the facilitation of synaptic communication between two neurons. Chronic stress or long-term elevation of glucocorticoids are the leading etiological factors in the development of depression. Their direct implication as a cause of marked atrophy of prefrontal cortex (PFC) and hippocampus is well known. On the other hand, the amygdala undergoes hypertrophy in acute depression and atrophy during long-term depression. Correspondingly, chronic stress causes a decrease in BDNF concentration in these regions, along with distinctive changes in dendritic arborization and decreased cell proliferation. Opposite effects have been found to unfold in the amygdala, also contributing to higher stress reactivity. These changes correspond to the abnormal function of these structures, which is expressed by some symptoms of depression-higher stress reactivity, chronically elevated stress hormones, cognitive deficits, and rumination. Most importantly, patients with depression have been found to have lower levels of circulating BDNF. SSRIs have been able to normalize this decrease. Val66Met polymorphism in the bdnf gene leads to lower inducible expression of BDNF. Furthermore, the Met allele has been linked to increased amygdala reactivity to affective stimuli and higher trait anxiety. Another study found that carriers of Met allele were more prone to anxiety and depression as a function of early life stress. Moreover, Met allele carriers had lower hippocampal and prefrontal grey matter volume, which predicted a higher risk of depression. There is also some evidence that suicide cases have lower BDNF expression in the prefrontal cortex and hippocampus in comparison to controlsand simultaneously lower mTOR expression and proteins under its control. However, there are several inconsistencies, such as differential up-or down-regulation of BDNF outside of the above-mentioned areas. This might suggest that altered neurotrophic signalization is not the direct cause of depression, but rather a link in the pathomechanism.
In the following section, we have summarized the molecular mechanisms and effects on animals and humans of several naturally occurring psychoplastogens, including serotonergic psychedelics and flavones (Figure). Serotonergic psychedelics are a broad group, based mostly around the indole ring or phenetylamine backbone. Among many others, these include psilocybin, produced by several Psilocybe spp., N,N-dimethyltryptamine (DMT), produced by Psychotria viridis, mescaline, produced by several North American cacti, and lysergic acid diethylamide (LSD), a derivate of ergotamine, produced by Claviceps spp.. 7,8-dihydroxyflavone (7,8-DHF) is produced by several plants, including the weed Tridax procumbens and a tree Godmania aesculifolia, commonly found in the Western Hemisphere tropics and trees in the widespread Primula genus. All flavones are based around the same chemical backbone and are a subset of the larger class of flavonoids. pharmacological potency without the need for modification. Since psychoplastogens work through distinct mechanisms (although ultimately converging), their mechanisms and effects have been described separately.
In general, serotonergic psychedelics possess a broad spectrum of receptor activity. Their effects are most commonly derived from the 5-hydroxytryptamine 2A receptor (5-HT2AR) activation. They also jointly activate 5-HT2B and 5-HT2C receptors, while some of them express 5-HT1AR activity. Other minor effects are derived from their adrenergic, dopaminergic, and histaminergic activity. 5-HT2AR is a Gq/11 coupled metabotropic receptor and leads to activation of phospholipase Cβ (PLCβ), hence the rise of [Ca 2+ ] and activation of PKC. This leads to excitatory postsynaptic currentsand activation of mitogen-activated protein kinase (MAPK). Interestingly, 5-HT2AR forms a heterodimer with metabotropic glutamate receptor 2 (mGluR2), inhibiting the activity of each other upon activation. Binding of psychedelic agonists to 5-HT2AR leads to a particular change in conformation and to inhibition of mGluR2, while the activation of mGluR2 by glutamate leads to inhibition of 5-HT2AR activity. This leads to inhibition of either phospholipase A2 (PLA2) or PLCβ, respectively. This gives rise to "biased agonism"and has been described to play a role in differential activation of down-stream pathways on 5-HT2A receptor activation. Though possessing similar chemical structure and binding at the same binding site, there appears to be an important difference between psychedelic and non-psychedelic 5-HT2AR agonists (such as lisuride or ergotamine). Serotonergic psychedelics also up-regulate PLA2, in addition to PLCβ, when compared to serotonin. This is achieved by stabilization of receptor in different conformation, which preferentially interacts with Gi/o rather than Gq α-subunit of G protein heterocomplex. Psilocin has been found to activate PLA2 with 30-fold potency over PLCβ when compared to serotonin. However, Research on their neuropsychiatric effects was initiated in the second half of the last century, though works on 7,8-DHF have appeared only recently. All of these compounds, except psilocybin (a prodrug to psilocin), are active drugs. Furthermore, all of them show high and robust pharmacological potency without the need for modification. Since psychoplastogens work through distinct mechanisms (although ultimately converging), their mechanisms and effects have been described separately.
In general, serotonergic psychedelics possess a broad spectrum of receptor activity. Their effects are most commonly derived from the 5-hydroxytryptamine 2A receptor (5-HT 2A R) activation. They also jointly activate 5-HT 2B and 5-HT 2C receptors, while some of them express 5-HT 1A R activity. Other minor effects are derived from their adrenergic, dopaminergic, and histaminergic activity. 5-HT 2A R is a G q/11 coupled metabotropic receptor and leads to activation of phospholipase Cβ (PLCβ), hence the rise of [Ca 2+ ] and activation of PKC. This leads to excitatory postsynaptic currentsand activation of mitogen-activated protein kinase (MAPK). Interestingly, 5-HT 2A R forms a heterodimer with metabotropic glutamate receptor 2 (mGluR2), inhibiting the activity of each other upon activation. Binding of psychedelic agonists to 5-HT 2A R leads to a particular change in conformation and to inhibition of mGluR2, while the activation of mGluR2 by glutamate leads to inhibition of 5-HT 2A R activity. This leads to inhibition of either phospholipase A2 (PLA2) or PLCβ, respectively. This gives rise to "biased agonism"and has been described to play a role in differential activation of down-stream pathways on 5-HT 2A receptor activation. Though possessing similar chemical structure and binding at the same binding site, there appears to be an important difference between psychedelic and non-psychedelic 5-HT 2A R agonists (such as lisuride or ergotamine). Serotonergic psychedelics also up-regulate PLA2, in addition to PLCβ, when compared to serotonin. This is achieved by stabilization of receptor in different conformation, which preferentially interacts with G i/o rather than G q α-subunit of G protein heterocomplex. Psilocin has been found to activate PLA2 with 30-fold potency over PLCβ when compared to serotonin. However, the PLCβ activation is still physiologically relevant. More recently, psychedelics activating 5-HT 2A receptors have been found to activate mTOR and increase neurite length, the number of dendrite spines, and overall network complexity, which is the first step, suggesting a possible therapeutic use.
5-HT 2A Rs are typically expressed at dendrites of glutamatergic neurons in PFC, with the strongest expression in layer V pyramidal neurons. Activation of these receptors leads to an increase in excitatory post-synaptic potentials (EPSPs). Simultaneously, 5-HT 1A R is present at the initial segment of the same neurons and drive inhibition of local currents. Functional integration of these two receptors might work as a gain control mechanism of incoming excitatory signalization, thus modulating percepts or mental representations coming to working memory. Medial prefrontal cortex (mPFC) portion of these neurons projects to the basolateral amygdala, where they exert inhibitory tone via GABA neurons and decrease the amygdala reactivity. These connections are thought to form a basis for fear extinction learning. Several studies on the effects of 5-HT 2A R agonists on anxious and depression-like behavior have been performed. Their effects are summarized in Table. For example, a synthetic 5-HT 2A R agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) has an anxiolytic effect in the four-plate test and elevated plus maze (EPM). Effects of natural psychoplastogens psilocybin and DMT have been explored in fear extinction protocols and forced swim test (FST). First, psilocybin has cue-potentiated fear on the first extinction trial, and DMT has shown post-acute anxiogenic effects. However, both substances have been shown to generally facilitate the extinction of fear conditioned by a cue, but not by context, which may have been mediated by its action on the amygdala. This two-way effect is consistent with the observation that the effects of psychedelics in humans are heavily dependent on the context in which they are used. In other words, they induce emotional lability and potentiate both positive and negative emotions. Both substances also decrease locomotion in EPM, suggesting that increased swimming is not due to a general increase in locomotor activity. In addition to receptor stimulation studies, a 5-HT 2A R knock-out mice have shown marked anxious and depressive-like behavior in comparison to wild-type mice. However, one study found no effects of psilocybin and psilocin on anxiety and depressive-like behavior. Authors noted that they might have used an inappropriate model-Flinders Sensitive Line, a strain developed for the screening of antidepressant drugs. They further hypothesized that low basal expression of 5-HT 2A R in the frontal cortex and hippocampus in this strain was potentially responsible for negative results. Remarkably, these substances produce positive effects hours to days after administration, despite the fact that they are cleared out in minutes to hours. Thus, these effects must be produced by persistent changes to brain function. Positive effects might be primarily exerted in mPFC, as it is responsible for fear extinction memory and direct inhibition of the amygdala. Moreover, lesion studies show that the destruction of mPFC produces a depression-like phenotype in rodents. Dysfunction of this region is known to play a role in depression and is related to amygdalar hyperactivation in response to negative stimuli in humans. Besides its inhibitory tone on the amygdala, it also works as a hub within the default mode network (DMN), which is also found to be deregulated in depression(see the section on human studies below).
Psychedelics are well known to cause visual illusions, (pseudo-)hallucinations, synesthesia, changes in mood (both positive and negative), changes in body-space relations, alterations in time and space, depersonalization, derealization and ego dissolution. These effects are completely blocked by pretreatment with selective 5-HT 2A R antagonists (e.g., ketanserin), or atypical antipsychotics (e.g., risperidone). Several studies on therapeutic effects of psychedelics, including depression, end-of-life existential distress, substance abuse disorders, have been carried out with promising results. The summary of key studies is provided in Table. Out of all-natural psychedelics, research on psilocybin has reached the most promising therapeutic potential. It is labeled as a "breakthrough therapy" for MDD by U.S. Food and Drug Administration and approved for phase 3 clinical trial by European Medicines Agency. Additionally, phase 2 clinical trial on LSD for depression treatment is currently conducted by Bogwart and colleagues. Psilocybin has produced a significant decrease in depression and trait anxiety measures in patients with moderate to severe treatment-resistant depression. The effects are sustained from 1 week to at least 6 months after treatment. It is also used as a possible treatment of existential distress in patients with terminal cancer. In two studies, psilocybin has induced a marked decrease in depression and anxiety measures at day one after administration and lasted at least up to 26 weeks post-treatment. Moreover, overall well-being and life satisfaction are improved in most participants. Comparable results are achieved with LSD. Similar studies have been performed with ayahuasca, an Amazonian brew containing DMT and monoamine oxidase inhibitors. Early studies have reported on the positive psychological effects of ayahuasca in religious context. Subsequent clinical studies have explored its effects on patients suffering from recurrent or treatment-resistant depression. Ayahuasca has produced immediate, robust, and significant decrease in anxiety and depression symptoms, at least up to 3 weeks follow-up. These positive changes might be explained by the remodeling of brain networks involved in the development of depression. It has been found out that psychedelics cause acute disruption of the default mode network (DMN) by reduction of activity of its structures and connectivity between them. In contrast, psilocybin promotes the post-acute strengthening of DMN. Functional connectivity within DMN and activity of its constituents have been independently found to be altered in patients with depression and associated with self-centered negative rumination. Carhart-Harris et al.hypothesized that disruption of DMN by psychedelics facilitates remodeling of the connections responsible for negative rumination. Co-administration with psychotherapy helps to better integrate the insights and subsequently change patients' attitudes towards issues. Moreover, psilocybin induces positive affect in healthy volunteers, which is correlated with a decrease in amygdala reactivity to neutral and negative stimuli. It also reduces the connectivity of the amygdala in emotional face discrimination. The effects were significant after session 1 until cross-over 7 weeks later. After cross-over, both groups showed a substantial reduction in depression symptoms and anxiety compared to baseline. These effects were sustained at a 6.5-month follow-up and were mediated by mystical-like experiences on session day. CBF (cerebral blood flow); LSD (lysergic acid diethylamide); DMT (N,N-dimethyltryptamine). 3.2. 7,8-dihydroxyflavone and its Derivatives 3.2.1. Mechanism of Action 7,8-DHF specifically binds to the TrkB receptor extracellular domain and acts as a selective TrkB agonist, mimicking the physiological actions of BDNF. This is a unique mechanism of action since only a limited selection of compounds besides complex peptides can activate this receptor. Since 7,8-dihydroxyflavone is not a peptide, it is considered a small molecule activator of TrkB (only 254 Da, which is t ~1% of the size of the active BDNF dimer). However, these two ligands may utilize distinct mechanisms to activate TrkB receptors. Liu et al.demonstrated that 7,8-DHF bound tightly to TrkB extracellular domain using two independent biophysical approaches. BDNF transiently activated TrkB, leading to receptor internalization and ubiquitination/degradation. In contrast, 7,8-DHF-triggered TrkB phosphorylation lasted for hours, and the internalized receptors were not degraded. Thus, 7,8-DHF acted as a robust TrkB agonist, passing the blood-brain barrier and exhibiting promising therapeutic efficacy in a variety of neurological and psychological diseases. A structure-activity relationship study has shown that the catechol moiety in 7,8-DHF is critical for its agonistic effect. Liu et al.showed that the catechol group was extensively conjugated by glucuronidation, sulfation, and methylation in the liver, leading to poor oral bioavailability. Chen et al.synthesized 7,8-DHF derivatives to modify the catechol group. They found that prodrug R13 exhibited good absorption and was readily hydrolyzed into 7,8-DHF in liver microsomes. Notably, R13 had a very long half-life, and it improved 7,8-DHF's oral bioavailability from 4.6% to ∼10.5%. The plasma concentration and brain exposure were also significantly enhanced. Chronic oral administration of R13 alleviated Aβ deposition, attenuated the loss of hippocampal synapse, and ameliorated memory deficits in a dose-dependent manner. Although 7,8-DHF has been able to promote TrkB activation in vivo, it has failed to do so in vitro. The authors reported the absence of TrkB, extracellular signal-regulated kinases (ERK), and AKT phosphorylation in embryonic cortical neuron cultures. They proposed that discrepancies might have been caused by the conversion of 7,8-DHF to some other active metabolite, transactivation of TrkB through activation of G proteins or receptor tyrosine kinases. Furthermore, they proposed that TrkB phosphorylation by 7,8-DHF in vivo might be a methodological artifact.
It has been shown that systemic administration of 7,8-DHF can induce BDNF-like behavioral phenotypes, such as enhanced learning and memory and antistress or antidepressant-like effects in rodents in a TrkB-dependent manner. Key studies are summarized in Table. Administration of 7,8-DHF into BDNF conditional knockout mice has also triggered TrkB activation in the BDNF-depleted cortex. Hence, 7,8-DHF induces TrkB activation in the mouse brain in a BDNF-independent manner. Intraperitoneal injection of 7,8-DHF improved behavioral tests, specifically, forced swim test and tail suspension test, in the mouse model of depression. Since not many studies on the effects of 7,8-DHF in depression models were performed, it is worthwhile to mention other studies which explore its application in models of diseases with neurodegenerative component (as depression partially is). For instance, 7,8-DHF prevented the degeneration of the vestibular ganglion in mice lacking BDNF and promotes axon regeneration. It also rescued synaptic plasticity in cognitively impaired aged rats. Remarkably, 7,8-DHF has regulated the BDNF deficiency-induced learning and memory phenotypes in mice genetically deficient for the proprotein convertase PC7. Mounting evidence has also demonstrated neuronal survival in various models, including dopaminergic neurons, retinal ganglion cells [100], and motoneurons [101], after 7,8-DHF administration. 7,8-DHF also has potent neurotrophic effects in various neurological disease models, including stroke [102], and neurodegenerative diseases, including Huntington's disease [103] and Alzheimer's disease (AD). Several studies have indicated that 7,8-DHF rescues memory deficits in different AD animal models, restoring deficient TrkB signaling without affecting endogenous BDNF levels. It has improved spatial memory and increased thin spine density in an AD mouse model. These findings provide a groundwork for proceeding the prodrug into clinical trials.
To date, no human studies on the treatment of MDD with 7,8-DHF have been performed. Since the compound has shown promising results in animal models, it is reasonable to expect some amelioration (at least in the cognitive domain) in these patients too.
Physiological side effects caused by psychedelics are usually moderate at best. Most commonly, they include clinically insignificant elevation of heart rate and blood pressure, headaches/migraines, GIT discomfort with nausea, vomiting, or diarrhea (especially in the case of ayahuasca). Their toxicity is particularly low. Psychological adverse effects are of greater interest. Psychedelics may cause transient but tolerable confusion, perceptual pseudo-/hallucinations, vivid imagination, dysphoria, anxiety, fear, and paranoia. For example, Ross et al.commented that at the time of their study, approximately 2000 doses of psilocybin had been safely administered in the US and Europe without any serious adverse event. It is important to note that in these studies, the administration was performed under carefully controlled conditions with strict exclusion criteria and with medical and psychological aid at hand. In case of severe adverse events, the staff is usually equipped with tranquilizers (benzodiazepines and antipsychotics). Nevertheless, population studies indicate that there is no association between life-time psychedelics use and any mental illness, suicidal ideation, or suicide attempts. Even more surprisingly, the use of psychedelics has predicted a lower need for mental health treatment in the past year in comparison to the general population. Despite their relative safety, study protocols should implement strict exclusion criteria for susceptible individuals with a personal or family history of schizophrenia, mania, or bipolar disorder (BD). Susceptible individuals (especially BD patients in the first depressive episode) without personal or family history might be at risk of developing of (at least) transient psychosis. In general, authors conclude that psychedelics are generally safe. No prolonged psychotic-like reaction has been reported in any trial in the last 30 years [108]. On the other hand, studies on these substances from the pre-prohibition era show that the condition of people with existing psychotic diseases (schizophrenia and mania) aggravates after treatment [106].
The development of novel therapeutic compounds for the treatment of depression has trickled down in the last decade. Since pharmaceutical companies are reluctant to engage in high-risk development of drugs for psychiatric illnesses, it is of utmost importance to look for novel therapies. The recent adoption of ketamine for treatment-resistant depression is an important improvement of the situation. Growing evidence on the effects of serotonergic psychedelics suggests that they might prove to be an important psychiatric medication of the future. Similar promising results from studies on methylenedioxymethamphetamine (MDMA), currently in phase 3 of clinical trials, confirm and extend the validity of fast-acting antidepressants. Furthermore, the risk of adverse effects and substance abuse of these compounds is relatively low and/or short-lasting. Nevertheless, such concerns need to be taken into account. It is tempting to consider that 7,8-DHF is a better alternative to serotonergic psychedelics because studies have not reported on typical proxies of hallucinogenic properties in animals. These proxies include head-twitch response, prepulse inhibition disruption (PPI), or drug discrimination essays. Only one relevant study has shown that 7,8-DHF suppresses PPI deficits induced by methamphetamine. This advantage is speculative at best. On the other hand, BDNF-TrkB signaling appears to be involved in neuropathic pain and promotes the strengthening of pathological nociceptive signals at the level of the spinal cord and anterior cingular cortex (ACC) after nerve injury. This might be a contraindicated condition if 7,8-DHF is ever used in clinical studies. A more viable alternative to classical psychedelics and 7,8-DHF might have been found by. They synthesized DMT isosteres with psychoplastogenic activity comparable to ketamine but with lower hallucinogenic potential. More studies are needed to confirm its effects and assess their safety. But still, mind-altering properties of psychedelics might be essential since they mediate therapeutic effects. Compared to conventional, long-term treatment with reuptake inhibitors, these substances produce therapeutic effects after two to three therapeutic sessions, carry a low risk of non-compliance, and produce no withdrawal symptoms.
Create a free account to open full-text PDFs.
Ray, T. S. · PLOS ONE (2010)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Cameron, L. P., Benson, C. J., Dunlap, L. E. · ACS Chemical Neuroscience (2018)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Jefsen, O., Højgaard, K., Christiansen, S. L. et al. · Acta Neuropsychiatrica (2019)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Kirchner, K. · Journal of Psychopharmacology (2014)
Santos, R. G., Landeira-Fernandez, J., Strassman, R. J. et al. · Journal of Ethnopharmacology (2007)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Grimm, O., Kraehenmann, R., Preller, K. H. et al. · European Neuropsychopharmacology (2018)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A. et al. · Lancet Psychiatry (2018)
Papers in Blossom that reference this study
Ona, G., Bouso, J. C. · Neuroscience and Biobehavioral Reviews (2020)